SRH Advisors’s Connect Biopharma Holdings CNTB Stock Holding History

SRH Advisors’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,200	Closed	-$2K	–	302
2022 Q3	$2K	Buy	+1,200	New	+$1.44K	﹤0.01%	291

Other funds holding CNTB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

SRH Advisors's CNTB Position: Q4 2022 in Review

SRH Advisors sold out of Connect Biopharma Holdings (CNTB) in Q4 2022, closing a stake of 1,200 shares — an estimated $2K sold.

SRH Advisors first reported a position in CNTB in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 20 funds tracked by Wall St. Rank hold CNTB as of Q4 2022.

SRH Advisors reported no remaining Connect Biopharma Holdings position as of Q4 2022 after selling out during the quarter.
SRH Advisors sold 1,200 Connect Biopharma Holdings shares in Q4 2022, an estimated $2K.
SRH Advisors first reported a position in Connect Biopharma Holdings in Q3 2022 and held it in 1 quarter.
SRH Advisors's Connect Biopharma Holdings position peaked at $2K in Q3 2022.
20 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q4 2022.

Based on SRH Advisors's 13F filing for Q4 2022, filed 1 Feb 2023.